What happened with DHR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Danaher sells hospitals and laboratories instruments and supplies for testing patient samples, diagnosing disease and guiding treatment. Diagnostics is its largest business segment. Its Biotechnology and Life Sciences businesses together account for the rest of its sales, supplying pharmaceutical companies, biotechnology companies and researchers with tools to study biological materials and develop and manufacture medicines. Life Sciences also sells filtration products used in industrial manufacturing.
The company sells mainly through its own sales teams. Equipment purchases bring in revenue, but most sales recur as customers replenish consumables and buy services. Many consumables are essential to running Danaher equipment and need replacement after one use or a limited period; others, such as custom DNA and RNA, are sold independently.
Demand depends on customers’ research funding, equipment budgets and drug-development and manufacturing activity. Respiratory-disease testing also makes part of Diagnostics sensitive to infection seasons. Certain medical products require clearance or approval from the FDA or comparable regulators, which limits when and for which uses Danaher can sell them.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Danaher depends on demand for biological-drug production, research and clinical testing; beyond this list, watch bioprocessing rivals Sartorius and Merck KGaA and diagnostics rival Roche.
Thermo Fisher Scientific competes with Danaher for pharmaceutical companies’ and laboratories’ spending on research tools, biological-drug production supplies and diagnostic products. Its sales to pharmaceutical and biotechnology customers offer a broad read on demand across these overlapping businesses.
Repligen Corp competes with Danaher’s Cytiva to supply drug manufacturers with technologies that filter and separate biological materials, including filtration and chromatography systems. Watch its consumables demand alongside Danaher’s recovery in purchases by large pharmaceutical companies and contract drug manufacturers.
Bio-Rad competes with Danaher for research and healthcare laboratories’ purchases of life-science instruments, reagents and clinical diagnostic systems. Read its research and diagnostic sales separately: clinical diagnostics accounted for about 60% of its 2025 net sales.
Agilent Technologies competes with Danaher’s SCIEX and Leica for laboratories’ mass spectrometry and pathology purchases, as well as consumables and services. Its CrossLab consumables can serve customers regardless of instrument brand, so those sales need not track Agilent’s own instrument sales.
Revvity competes with Danaher for research and clinical laboratories’ spending on cell, gene and protein research tools and diagnostic instruments and reagents. Its sales to academic and government researchers are worth watching against the weaker funding that reduced Danaher’s research demand.
QIAGEN competes with Danaher to help research and diagnostic laboratories prepare samples and extract and detect molecular information, selling instruments and consumables for molecular testing. Its consumables and related revenue is the line to watch for demand beyond new instrument purchases.
Waters competes with Danaher for pharmaceutical research and testing laboratories’ purchases of mass spectrometry systems and consumables that separate sample components, including chromatography columns. Watch its column sales: Waters says a larger installed base of its instruments can support that business.
Avantor competes with Danaher to supply biological-drug manufacturers with single-use assemblies, products for separating materials by chromatography and fluid-handling supplies. Its Bioscience Production business is the relevant line to watch, rather than its broader laboratory distribution business.
Bruker competes with Danaher for life-science and biopharmaceutical laboratories’ purchases of mass spectrometry and microscopy instruments. Its news on these instruments is more relevant to Danaher’s research-tool business than Bruker’s broader industrial offerings.
Bio-Techne competes with Danaher for drug-discovery and life-science laboratories’ purchases of research reagents, protein-analysis tools and assays. Its Protein Sciences sales are the closest line to watch for this overlap.
Abbott competes with Danaher to supply hospitals and laboratories with clinical laboratory, molecular and acute-care testing systems and consumables.
BD competes with Danaher to sell life-science and diagnostic products to researchers and clinical laboratories. Watch the planned transfer of its Biosciences and Diagnostic Solutions business to Waters: the supplied filing says it remains with BD until that transaction is completed.
Illumina and Danaher both depend on academic, government and biopharmaceutical laboratories’ spending: Illumina sells sequencing instruments and reagents, while Danaher sells genomic research tools. Watch Illumina’s sequencing demand for a read on these research budgets, which also affect Danaher’s equipment and consumables sales.
Danaher Corporation earningsThis company
Danaher's report will show whether demand for bioprocessing and diagnostic consumables is broadening growth across its businesses and holding up margins.
Read core sales alongside operating margin for each segment. Core sales exclude acquired businesses and currency changes, helping show the underlying sales trend. If consumables sales grow and margins hold, customers are buying more and that growth is not being swallowed by costs or product mix. If growth is concentrated in Biotechnology while Life Sciences sales and margin remain weak, research-tool demand has not recovered and Danaher's growth is still uneven.
Abbott Laboratories earningsABT
Abbott's report will show whether hospitals and laboratories are buying clinical, molecular and acute-care testing products, giving a read on the market Danaher's Diagnostics business also serves.
Watch Abbott's diagnostics sales and its commentary on demand. Stronger sales suggest hospitals and laboratories are still buying testing products, supporting the market Danaher's Diagnostics business serves—but they do not show that Danaher gained share. Weaker sales point to pressure among shared customers and a softer demand backdrop for Danaher's diagnostic consumables and instruments.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher's report will show whether pharmaceutical and biotechnology customers are still spending across research, production and diagnostic markets that also matter to Danaher.
Watch Thermo Fisher's sales to pharmaceutical and biotechnology customers. Stronger sales suggest those customers are still buying research tools and biological-drug production supplies, supporting demand across several Danaher businesses. Weaker sales point to pressure on customer spending and a tougher backdrop for Danaher. The companies sell different product mixes, so this is a market signal, not a prediction of Danaher's sales.
Repligen Corp earningsRGEN
Repligen's report will show whether drug makers and contract manufacturers are buying filtration and chromatography consumables, a market where it competes with Danaher's Cytiva.
Read Repligen's consumables demand alongside sales of Danaher's bioprocessing consumables. Stronger demand at Repligen suggests drug makers and contract development and manufacturing organizations are buying more in this market, which could also lift conditions for Cytiva. Weaker demand suggests those customers' purchases have not broadly recovered, leaving Danaher's bioprocessing consumables facing a soft market too.
Fed Interest Rate Decision
Danaher’s interest-rate exposure means the Fed’s policy rate, which influences borrowing costs across the economy, can change what it pays on debt that reprices and how much interest it earns on cash.
Expected4.0%Last release4.0%
If it comes in above expectations
If the policy rate is higher than expected, Danaher could pay more on debt that reprices, weighing on earnings; higher rates could also increase interest earned on its cash.
If it comes in below expectations
If the policy rate is lower than expected, Danaher could pay less on debt that reprices, easing pressure on earnings; lower rates could also reduce interest earned on its cash.
Revvity, Inc. earningsRVTY
Revvity's report will show whether academic and government researchers are buying more, offering a read on demand for Danaher's Life Sciences research tools.
Watch Revvity's sales to academic and government researchers. Improving sales suggest research institutions may be loosening their purchasing budgets, which could help demand for Danaher's research tools and consumables recover. Continued weakness suggests funding pressure remains and Danaher's research customers may keep limiting purchases.
